Hepatitis Forums
Advanced Liver Disease Main Forums => Advanced Liver Disease => Topic started by: Hep Editors on July 23, 2018, 10:05:15 am
-
Personalized T-cell immunotherapy reduced the risk of liver cancer recurrence and may lead to tumor regression, according to research presented at the 2018 EASL International Liver Congress (EASL 2018) last month in Paris.
In one study, people who received immunotherapy produced from their own T cells after surgery or local therapies were less likely to experience hepatocellular carcinoma (HCC) recurrence and had significantly longer overall survival over five years of follow-up.
Read more...
https://www.hepmag.com/article/personalized-immunotherapy-shows-promise-liver-cancer